Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.

Canva, Australia’s biggest design platform, has had its internal valuation cut by $10 billion AUD (approx. $7.1 billion USD). An independent assess...

Canva’s Biggest Backers Wipe $10 Billion From Valuation as AI Reality Bites

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Sell rating on Novavax, with a price target of $7.00. Accor...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVAX	$10.23	-1.11%	3.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVAX	$10.23	-1.1%	3.13M
3
4
5
6

NVAX

Get Novavax, Inc. Data in Excel

Get Novavax, Inc. Data in Excel